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Predictors of de novo atrial fibrillation in a 
non-cardiac intensive care unit
ORIGINAL ARTICLE
INTRODUCTION
The prevalence of atrial fibrillation (AF) is high, reaching 10% in individuals 
over 80 years of age.(1-3) AF is associated with longer stays in the hospital and 
intensive care unit (ICU),(2,4) and de novo AF in critically ill patients is associated 
with higher mortality.(5) The clinical complexity of patients in the ICU requires 
rapid diagnosis and effective treatment of this condition.(6-8)
In this context, knowledge of the epidemiology of this event in critically 
patients becomes important. The incidence of de novo AF ranges from 5 to 
65%, depending on the type of ICU, and is higher in patients undergoing 
cardiac surgery.(9-18) In turn, the large variation in the incidence of de novo AF 
in the various types of ICU can be explained by different predictors of AF 
occurrence.
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Objective: To assess the predictors of 
de novo atrial fibrillation in patients in a 
non-cardiac intensive care unit.
Methods: A total of 418 hospitalized 
patients were analyzed between 
January and September 2016 in a non-
cardiac intensive care unit. Clinical 
characteristics, interventions, and 
biochemical markers were recorded 
during hospitalization. In-hospital 
mortality and length of hospital stay 
in the intensive care unit were also 
evaluated.
Results: A total of 310 patients were 
included. The mean age of the patients 
was 61.0 ± 18.3 years, 49.4% were male, 
and 23.5% presented de novo atrial 
fibrillation. The multivariate model 
identified previous stroke (OR = 10.09; 
p = 0.016) and elevated levels of pro-B 
type natriuretic peptide (proBNP, OR 
= 1.28 for each 1,000pg/mL increment; 
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p = 0.004) as independent predictors of 
de novo atrial fibrillation. Analysis of the 
proBNP receiver operating characteristic 
curve for prediction of de novo atrial 
fibrillation revealed an area under the 
curve of 0.816 (p < 0.001), with a 
sensitivity of 65.2% and a specificity of 
82% for proBNP > 5,666pg/mL. There 
were no differences in mortality (p = 
0.370), but the lengths of hospital stay 
(p = 0.002) and stay in the intensive care 
unit (p = 0.031) were higher in patients 
with de novo atrial fibrillation.
Conclusions: A history of previous 
stroke and elevated proBNP during 
hospitalization were independent 
predictors of de novo atrial fibrillation in 
the polyvalent intensive care unit. The 
proBNP is a useful and easy- and quick-
access tool in the stratification of atrial 
fibrillation risk.
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Some of these predictors of de novo AF have already 
been described in the literature, especially in critical cardiac 
patients, such as advanced age, greater severity score on 
admission, surgical or post-trauma admission, occurrence 
of sepsis, and need for ventilatory or catecholamine 
support. However, for medical and non-cardiac surgical 
ICU patients, there is a paucity of data in the literature 
regarding predictors of de novo AF.(4)
Therefore, the objective of this study was to investigate 
the predictive factors of de novo AF in patients in a non-
cardiac polyvalent ICU (critically ill and non-cardiac 
surgical patients). As secondary objectives, the incidence 
of de novo AF and its prognostic impact in terms of 
in-hospital mortality and length of hospital and ICU stay 
were also evaluated.
METHODS
A sample of patients hospitalized during a period of 
9 months (January 1, 2016 to September 30, 2016) in 
a non-cardiac polyvalent ICU at the Fernando Fonseca 
Hospital, Lisbon, Portugal, were retrospectively and 
consecutively analyzed.
The data were obtained through clinical consultations 
and were complemented by analytical and other diagnostic 
evaluations. The Hospital Ethics Committee approved the 
study, and informed consent was not required given the 
study’s observational nature.
The ICU had 14 beds. Patients with a pathology 
requiring mechanical ventilation, trauma patients, and 
non-cardiac surgery patients were admitted.
All patients were under continuous cardiac monitoring 
with three leads. The presence of an absolutely irregular 
RR interval with no apparent P waves or the replacement 
of these by AF waves was classified as AF, with subsequent 
confirmation on a 12-lead electrocardiogram. For 
classification as de novo AF, all patients with sinus rhythm 
on ICU admission and without any record of prior AF 
or atrial flutter (documented electrocardiographically, 
in a previous medical report or indicated by the patient 
and/or family) were considered. To this end, the 
national platform of medical records, called the Health 
Data Platform (Plataforma de Dados da Saúde), was 
also consulted. Patients with a definite pacemaker on 
admission or previous cardiac surgery, chest trauma, or 
pulmonary thromboembolism in the last year (the latter 
two associated with a higher risk of de novo AF) were 
excluded from this group.
Each patient was classified according to the reason for 
hospitalization: medical, surgical, or trauma. Each patient 
was further stratified on admission according to the in-
hospital mortality scores Acute Physiology and Chronic 
Health Evaluation II (APACHE II)(19) and Simplified 
Acute Physiology Score (SAPS II).(20)
The presence of the following cardiovascular disease 
and risk factors was evaluated: arterial hypertension, 
dyslipidemia, diabetes mellitus, obesity, smoking, heart 
valve disease, heart failure (HF), and previous acute 
coronary syndrome. Individuals with at least 1 year of 
smoking cessation were considered former smokers/non-
smokers. The presence of heart valve disease was assumed 
in individuals with stenosis and/or moderate or severe 
failure of at least one valve, previously documented by an 
imaging method. Chronic obstructive pulmonary disease 
(COPD), obstructive sleep apnea syndrome, stroke, 
thyroid function disorders, and chronic kidney disease 
were also documented. The COPD definition of the 
Global Initiative for Chronic Obstructive Lung Disease 
was adopted.(21) In cases of kidney injury or a glomerular 
filtration rate of less than 60mL/min/1.73m2 for 3 
months or more, the presence of chronic kidney disease 
was assumed, according to the Kidney Disease Outcomes 
Quality Initiative of the National Kidney Foundation.(22) 
The infectious complications were recorded (nosocomial 
infection, sepsis, and septic shock), applying the criteria 
defined by the recommendations of the Surviving Sepsis 
Campaign.(23)
Information regarding the interventions performed 
up to the date of occurrence of AF were recorded. The 
peak/maximum values of C-reactive protein, serum 
creatinine, and pro-B type natriuretic peptide (proBNP) 
were also documented in all patients admitted to the 
ICU, as was the serum albumin nadir/minimum value 
during hospitalization until the date of occurrence of AF. 
Serial measurements of these biomarkers are part of the 
institutional protocol.
Statistical analysis
The demographic and clinical characteristics of 
the sample were analyzed using descriptive statistics. 
Continuous variables with normal distribution are 
expressed as the mean ± standard deviation (SD), and 
categorical variables as the number of patients in each 
category and corresponding percentages. Nonparametric 
continuous variables are expressed as medians and 
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interquartile ranges. Normal distribution was assessed 
using the Kolmogorov-Smirnov test.
Continuous variables were compared using the 
independent Student’s t test or Mann-Whitney U test, as 
appropriate. The association of categorical variables was 
assessed using the chi-square test or Fisher’s exact test.
Univariate logistic regression analysis was used to 
identify risk factors associated with the development of 
de novo AF during ICU stay. All variables considered as 
significant predictors of de novo AF (p < 0.05) were further 
analyzed using multivariate logistic regression. The results 
of the regression analysis are expressed as odds ratios 
(ORs) and 95% confidence intervals (95%CI), with p < 
0.05 being considered statistically significant.
The peak proBNP performance for prediction of de novo 
AF during ICU stay was tested using the receiver operating 
characteristic (ROC) curve. The Youden index was used 
to identify the optimal cutoff point of proBNP, thereby 
determining the sensitivity, specificity, accuracy, predictive 
values, and positive and negative likelihood ratios.
Lastly, the impacts of de novo AF on the lengths of stay 
in the hospital and ICU were analyzed using the Mann-
Whitney U test, and its impact on in-hospital mortality 
was analyzed using the Fisher exact test.
Statistical analysis was performed with the Statistical 
Package for Social Science (SPSS), version 22.0 (Chicago, 
IL, USA).
RESULTS
Of the 418 patients admitted to the ICU during the 
study period, 91 patients were excluded due to previous AF 
(21.8%), 11 due to the presence of a definitive pacemaker 
(3.4%), and 6 due to chest trauma (1.9%). No patient 
had a history of pulmonary thromboembolism in the last 
year or had been admitted to the ICU for cardiac surgery 
(Figure 1). Thus, 310 patients admitted during the study 
period were included in the final analysis.
The mean age of the patients was 61.0 ± 18.3 years, and 
49.4% (n = 153) were male. Table 1 summarizes the main 
demographic and clinical characteristics of our sample.
Table 2 summarizes the outcomes, complications 
(nosocomial infection, sepsis, septic shock, and death), 
the interventions performed during hospitalization, and 
the values of the laboratory markers studied.
During the study period, 73 patients with de novo AF 
(23.5%; 95%CI 18.9 - 28.7) were recorded. The incidence 
rates of de novo AF were 24.2% in males and 22.9% in 
females (p = 0.894). De novo AF occurred in 15.3% of 
Figure 1 - Flowchart of patient inclusion in the study. AF - atrial fibrillation; ICU - intensive 
care unit.
Table 1 - General population characteristics (n = 310)
Variables
Age (years) 61.0 ± 18.3
Male sex 153 (49.4)
Type of admission
Medical 242 (78.1)
Surgical 57 (18.4)
Non-thoracic trauma 11 (3.5)
Risk factor/cardiovascular pathology
Arterial hypertension 166 (53.5)
Dyslipidemia 43 (13.9)
Diabetes mellitus 64 (20.6)
Obesity 23 (7.4)
Smoking 41(13.2)
Heart failure 35 (11.3)
Valve disease 7 (2.3)
Acute coronary syndrome 24 (7.7)
Respiratory disease
Chronic obstructive pulmonary disease 41 (13.2)
Obstructive sleep apnea syndrome 8 (2.6)
Stroke 57 (18.4)
Chronic kidney disease 36 (11.6)
Thyroid dysfunction 10 (3.2)
APACHE II 16 (10 - 26)
SAPS II 36 (23 - 56)
SD - standard deviation; APACHE II - Acute Physiology and Chronic Health Evaluation II; 
SAPS II - Simplified Acute Physiology Score. Values are expressed as the means ± standard 
deviations, n (%), or medians (interquartile ranges).
medical admissions, 15.8% of surgical admissions, and 
9.1% of admissions due to non-thoracic trauma.
Table 3 summarizes the general characteristics of the 
population, according to the presence or not of de novo 
AF (univariate analysis). Upon admission, patients with 
de novo AF were significantly older (70.1 ± 14.7 years 
versus 58.1 ± 18.5 years; p < 0.001) and had higher 
baseline prevalence rates of arterial hypertension (68.5% 
versus 48.9%; p = 0.005), HF (26.0% versus 6.8%; p < 
0.001), valve disease (8.2% versus 0.4%; p = 0.001), stroke 
(27.4% versus 15.6%; p = 0.037), and thyroid dysfunction 
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Table 2 - Outcomes, complications, interventions performed, and laboratory 
markers (n = 310)
Infectious complications
Nosocomial infection 129 (41.6)
Sepsis 152 (49.0)
Septic shock 71 (22.9)
Interventions 
Catecholamine support 90 (29.0)
Non-invasive ventilation 43 (13.9)
Invasive mechanical ventilation 168 (54.2)
Days on invasive ventilation 1 (0 - 7)
Reintubation 13 (4.2)
Tracheotomy 23 (7.4)
Renal replacement 31 (10.0)
Central venous catheter 221 (71.3)
Laboratory markers
Peak serum creatinine (mg/dL) 1.37 (0.93 - 2.75)
Nadir serum albumin (g/dL) 2.85 ± 1.79
Peak C-reactive protein (mg/dL) 16.9 (6.3 - 28.8)
Peak proBNP (pg/mL) 4,640 (1,220 - 10,155)
Days of ICU stay 6 (3 - 13)
Days of hospital stay 9 (4 - 20)
In-hospital mortality 52 (16.8)
proBNP - pro-B type natriuretic peptide; ICU - intensive care unit. Values are expressed as n 
(%), medians (interquartile ranges), or means ± standard deviations.
(8.2% versus 1.7%; p = 0.007). All 6 patients with de novo 
AF and thyroid dysfunction had hypothyroidism. The 
median APACHE II scores (21 points versus 15 points) 
and SAPS II scores (47 points versus 34 points) were also 
significantly higher in patients with de novo AF (p = 0.004 
and p < 0.001, respectively).
Table 4 summarizes the complications, interventions 
performed during hospitalization, and values of the 
laboratory markers studied, according to the presence or 
not of de novo AF (univariate analysis). Patients with de 
novo AF had a higher prevalence of septic shock (37% versus 
18.6%; p = 0.007) and a greater need for catecholamine 
support (41.1% versus 25.3%; p = 0.012) and central 
venous catheterization (84.9% versus 67.1%; p = 0.003). 
The median peak values of serum creatinine (1.84mg/dL 
versus 1.22mg/dL) and peak proBNP (9,461pg/mL versus 
1,652pg/mL) were significantly higher in patients with de 
novo AF (p = 0.002 and p < 0.001, respectively).
Patients with prior HF (n = 35, 11.3%) had significantly 
higher levels of proBNP than those without HF (median 
9,017pg/mL versus 2,130pg/mL; p < 0.001). Considering 
the subgroup with de novo AF, the proBNP levels were 
Table 3 - Sample characteristics according to the presence or absence of de novo 
atrial fibrillation
De novo AF
(n = 73)
No
de novo AF
(n = 237)
p value
Age in years 70.1 ± 14.7 58.1 ± 18.5 < 0.001
Male sex 37 (50.7) 116 (48.9) 0.894
Type of admission
Medical 63 (86.3) 179 (75.5) 0.290
Surgical 9 (12.3) 48 (20.3)
Non-thoracic trauma 1 (1.4) 10 (4.2)
Risk factors/cardiovascular pathology
Arterial hypertension 50 (68.5) 116 (48.9) 0.005
Dyslipidemia 12 (16.4) 31 (13.1) 0.446
Diabetes mellitus 12 (16.4) 52 (21.9) 0.408
Obesity 4 (5.5) 19 (8.0) 0.613
Smoking 8 (11.0) 33 (13.9) 0.693
Heart failure 19 (26.0) 16 (6.8) < 0.001
Valve disease 6 (8.2) 1 (0.4) 0.001
Acute coronary syndrome 2 (2.7) 4 (1.7) 0.629
Respiratory disease
Chronic obstructive pulmonary disease 9 (12.3) 32 (13.5) 1.000
Obstructive sleep apnea syndrome 3 (4.1) 5 (2.1) 0.398
Stroke 20 (27.4) 37 (15.6) 0.037
Chronic kidney disease 10 (13.7) 26 (11.0) 0.534
Thyroid dysfunction 6 (8.2) 4 (1.7) 0.007
APACHE II 21 (12 - 28) 15 (10 - 24) 0.004
SAPS II 47 (33 - 65) 34 (22 - 51) < 0.001
AF - atrial fibrillation; APACHE II - Acute Physiology and Chronic Health Evaluation II; SAPS 
II - Simplified Acute Physiology Score. Values are expressed as the means ± standard 
deviations, n (%), or medians (interquartile ranges).
not significantly different between patients with and those 
without HF (median 11,068pg/mL versus 7,875pg/mL; 
p = 0.222).
After the selection of the significant predictors in 
the univariate analysis and their application in the 
multivariable model (Table 5), the presence of stroke (OR 
= 10.09; 95%CI 1.54 - 66.27; p = 0.016) and elevated 
proBNP values (OR = 1.28; 95%CI 1.086 - 1.520; p = 
0.004, for each 1,000pg/mL increment) were identified as 
independent predictors of de novo AF. 
The capacity of the proBNP peak to predict de novo AF 
during ICU stay was tested using the ROC curve; the area 
under curve (AUC) was 0.816 (95%CI 0.733 - 0.899; p 
< 0.001), demonstrating good performance (Figure 2). A 
proBNP value > 5,666pg/mL was identified as the optimal 
cutoff point for prediction of de novo AF, with a sensitivity 
of 65.2% and a specificity of 82% (Table 6).
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Table 4 - Complications, interventions performed, and laboratory markers 
according to the presence or absence of de novo atrial fibrillation
De novo AF
(n = 73)
No 
de novo AF
(n = 237)
p value
Infectious complications
Nosocomial infection 37 (50.7) 92 (38.8) 0.079
Sepsis 41 (56.2) 111 (46.8) 0.182
Septic shock 27 (37.0) 44 (18.6) 0.002
Interventions performed
Catecholamine support 30 (41.1) 60 (25.3) 0.012
Non-invasive ventilation 13 (17.8) 30 (12.7) 0.332
Invasive mechanical ventilation 44 (60.3) 124 (52.3) 0.283
Days on invasive ventilation 2 (0 - 10) 1 (0 - 6) 0.082
Reintubation 6 (8.2) 7 (3.0) 0.086
Tracheotomy 8 (11.0) 15 (6.4) 0.205
Renal replacement 11 (15.1) 20 (8.4) 0.118
Central venous catheter 62 (84.9) 159 (67.1) 0.003
Laboratory markers
Peak serum creatinine (mg/dL)
1.84
(1.09 - 3.65)
1.22
(0.89 - 2.41)
0.002
Nadir serum albumin (g/dL)
1.94
(1.55 - 2.42)
2.15
(1.65 - 2.64)
0.140
Peak C-reactive protein (mg/dL)
18.8
(9.81 - 28.8)
16.2
(5.8 - 28.8)
0.422
Peak proBNP (pg/mL)
9,461
(2,951 - 17,882)
1,652
(535 - 5,289)
< 0.001
AF - atrial fibrillation; proBNP - pro-B type natriuretic peptide. Values are expressed in n (%) 
or medians (interquartile ranges).
Table 5 - Multivariate model for prediction of de novo atrial fibrillation
Multivariate model* B OR 95%CI for OR p value
Age (per 1-year increment) 0.028 1.028 0.965 - 1.095 0.394
High blood pressure 0.936 2.550 0.482 - 13.487 0.271
Heart failure 0.997 2.711 0.447 - 16.438 0.278
Valve disease 19.818 4.04 x 108 0 0.999
Stroke 2.311 10.087 1.535 - 66.271 0.016
Thyroid dysfunction 2.407 11.105 0.784 - 157.2 0.075
APACHE II (per point increment) 0.140 1.150 0.990 - 1.336 0.067
SAPS II (per point increment) 0.062 1.064 0.987 - 1.146 0.104
Septic shock 1.584 0.940 0.872 - 1.013 0.162
Catecholamine support 0.528 1.696 0.247 - 11.624 0.591
Central venous catheter 0.239 1.269 0.157 - 10.292 0.823
Peak serum creatinine (per 1 mg/dL increment) 0.230 1.259 0.850 - 1.864 0.250
Peak proBNP (per 1,000 pg/mL increment) 0.250 1.284 1.086 - 1.520 0.004
B - coefficient B; OR - odds ratio; 95% CI - 95% confidence interval; APACHE II - Acute Physiology and Chronic Health Evaluation II; SAPS II - Simplified Acute Physiology Score; proBNP - pro-B 
type natriuretic peptide. * Only variables with p < 0.05 were included in the multivariable analysis.
Patients with de novo AF had significantly longer stays 
in the hospital (14 [7 - 23] days versus 8 [4 - 19] days; p 
= 0.002) and ICU (8 [4 - 16] days versus 6 [3 - 12] days; 
p = 0.031).
There were no significant differences in in-hospital 
mortality between patients with and those without de novo 
AF (20.5 versus 15.6%; p = 0.370).
DISCUSSION
Predictors of de novo atrial fibrillation: the role of 
proBNP
In our population, the presence of previous stroke and 
an elevated proBNP value were independent predictors 
of de novo AF. The existence of previously documented 
paroxysmal AF is one of the possible explanations for 
the high prevalence of prior stroke in this subgroup with 
de novo AF. Such individuals presented sinus rhythm on 
admission, though they may have had previous paroxysmal 
AF that manifested de novo during hospitalization.
In turn, proBNP was found to be a marker with good 
performance in predicting de novo AF in the ICU. To 
the best of our knowledge, there are no previous studies 
demonstrating this role of proBNP in general ICUs. A 
recent study by Chokengarmwong et al.(24) performed 
with 387 patients without AF revealed that proBNP at 
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Figure 2 - Receiver operating characteristic curve of peak pro-peptide natriuretic 
type B in the prediction of de novo atrial fibrillation. proBNP - pro-B type natriuretic peptide; 
AUC - area under the curve; 95%CI - 95% confidence interval.
Table 6 - Performance of pro-B type natriuretic peptide > 5,666 pg/mL in the 
prediction of de novo atrial fibrillation
Value 95% CI
Sensitivity (%) 65.2 62.2 - 68.2
Specificity (%) 82 79.5 - 84.3
Positive predictive value (%) 78.4 75.9 - 80.6
Negative predictive value (%) 70.2 68.3 - 72.1
Likelihood ratio for positive test 3.62 3.15 - 4.17
Likelihood ratio for negative test 0.42 0.39 - 0.46
Accuracy (%) 74.6 71.2 - 75.5
admission is a predictor of de novo AF in the first 3 days 
of hospitalization in a surgical and trauma ICU. In our 
study, proBNP > 5,666pg/mL showed good specificity 
and reasonable sensitivity in the prediction of de novo AF. 
However, the pathophysiological relationship between 
AF and proBNP still needs to be explained and may 
be attributed to atrial dilation, atrial fibrosis, or even 
decompensation of the underlying disease.(25) However, 
it seems more likely that proBNP, like troponin, is a 
consequence rather than a cause of stress and/or injury. 
Regardless of the type of pathophysiological relationship 
between AF and proBNP, elevated values of the latter 
allow the identification of patients at risk for AF. In turn, 
the early identification of these patients allows establishing 
early strategies for the prevention of AF.
High incidence of de novo atrial fibrillation in the 
general intensive care unit
The incidence of de novo AF observed in our medical 
non-cardiac surgical ICU was 23.5%, which is considered 
high in this type of ICU. Although several previous 
studies focused on cardiac and surgical populations,(10-14,26) 
our data suggest that de novo AF is also a fairly frequent 
problem in the polyvalent ICU. Previous studies on the 
incidence of de novo AF in general ICUs have shown 
that the frequency of these events can reach 7 to 15%. 
However, some of these studies focused on the incidence 
of supraventricular tachyarrhythmias, regardless of the 
type of arrhythmia;(4,17) in these studies, the incidence of 
AF may be lower.
The increased proportion of septic patients with 
nosocomial infection in the ICU during the period 
of our study may explain the high incidence of AF. In 
fact, inflammation is a common process in critically ill 
patients and may be a mechanism in the genesis of AF.(27) 
In critically ill patients, in addition to the infectious 
pathology, respiratory and cardiac pathologies, invasive 
procedures, and the use of mechanical ventilation and 
catecholamine support may be triggers of AF.(15)
Prognosis and prevention strategies
Previous studies have shown that AF is associated 
with higher in-hospital mortality in critically ill patients, 
especially in those with advanced age.(28) Although there 
were no significant differences in in-hospital mortality 
between patients with and those without de novo AF in 
our cohort, the median days of hospital and ICU stay 
were significantly higher in the latter. To a certain extent, 
prolonged hospitalization in patients with AF may be 
associated with increased morbidity and higher health 
costs. Thus, the prevention of AF plays a central role in 
critically ill patients at increased risk (here identified by 
elevated proBNP). Several prophylactic AF strategies 
have been described,(29,30) most of which are described in 
critically ill patients after thoracic surgery.
Our study has some limitations due to its retrospective 
nature and the heterogeneous group of patients. The small 
sample size and participation of a single hospital center 
also limit the capacity to infer the overall impact of AF 
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predictors. Recording the type and dose of catecholamines 
administered was not part of the study protocol, and 
these data may have a relevant impact on the prediction 
of AF. Data regarding the position of the central venous 
catheter and the possible rapid volume expansion phases 
may play relevant roles in both the proBNP levels and the 
prediction of AF; however, these data were not evaluated 
in the present study. Although the diagnostic sensitivity 
of proBNP should be not be considered a strong effect, 
this limitation is compensated at least partly by the 
considerable specificity of proBNP in detecting de novo 
AF in this population. Only a small proportion of patients 
had available echocardiographic parameters; therefore, 
these data were excluded from the analysis. However, 
proBNP has the advantage of being an easily accessible 
marker in non-cardiac ICUs.
CONCLUSIONS
History of previous stroke and elevated proBNP on 
admission were independent predictors of de novo atrial 
fibrillation in the polyvalent intensive care unit. ProBNP 
can be a useful and easily and quickly accessible tool to 
stratify the risk of atrial fibrillation. The high incidence 
of de novo atrial fibrillation in the polyvalent non-cardiac 
intensive care unit emphasizes the importance of timely 
recognition of this pathology.
Objetivo: Avaliar quais os preditores de fibrilação atrial de 
novo em doentes de uma unidade de cuidados intensivos não 
cardíaca.
Métodos: Foram analisados 418 doentes internados entre 
janeiro e setembro de 2016 em uma unidade de cuidados inten-
sivos não cardíaca. Registaram-se as características clínicas, as 
intervenções efetuadas e os marcadores bioquímicos durante a 
internação. Avaliaram-se ainda a mortalidade hospitalar e o tem-
po de internação hospitalar e na unidade de cuidados intensivos.
Resultados: Foram incluídos 310 doentes, com média de 
idades de 61,0 ± 18,3 anos, 49,4% do sexo masculino, 23,5% 
com fibrilação atrial de novo. O modelo multivariável identifi-
cou acidente vascular cerebral prévio (OR de 10,09; p = 0,016) e 
valores aumentados de proBNP (OR de 1,28 por cada aumento 
em 1.000pg/mL; p = 0,004) como preditores independentes de 
fibrilação atrial de novo. A análise por curva Característica de 
Operação do Receptor do proBNP para predição de fibrilação 
atrial de novo revelou área sob a curva de 0,816 (p < 0,001), com 
sensibilidade de 65,2% e especificidade de 82% para proBNP > 
5.666pg/mL. Não se verificaram diferenças na mortalidade (p = 
0,370), porém a duração da internação hospitalar (p = 0,002) e 
na unidade de cuidados intensivos (p = 0,031) foi superior nos 
doentes com fibrilação atrial de novo.
Conclusões: História de acidente vascular cerebral prévio e 
proBNP elevado em internação constituíram preditores inde-
pendentes de fibrilação atrial de novo na unidade de cuidados 
intensivos polivalente. O proBNP pode constituir ferramenta 
útil, de fácil e rápido acesso na estratificação do risco de fibrila-
ção atrial.
RESUMO
Descritores: Fibrilação atrial/epidemiologia; Incidência; Cui-
dados intensivos
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